
-
Rein Therapeutics NasdaqCM:RNTX Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Location: 12407 N. Mopac Expy., Austin, TX, 78758, United States | Website: https://www.reintx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
84.04M
Cash
12.87M
Avg Qtr Burn
-5.573M
Short % of Float
0.37%
Insider Ownership
0.15%
Institutional Own.
24.45%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LTI-03 Details Idiopathic pulmonary fibrosis | Phase 2 Data readout | |
LTI-01 Details Loculated pleural effusions | Phase 2a Update | |
ALRN-6924 Details Cancer, Breast cancer | Failed Discontinued | |
ALRN-6924 Details Cancer, Non-small cell lung carcinoma | Failed Discontinued | |
ALRN-6924 Details Cancer, Small cell lung cancer, Solid tumor/s | Failed Discontinued |